Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Phase 2
Completed
- Conditions
- GastrinomaPancreatic Polypeptide TumorRecurrent Islet Cell CarcinomaGlucagonomaInsulinomaRecurrent Pancreatic CancerSomatostatinomaStage IV Pancreatic CancerStage III Pancreatic Cancer
- Interventions
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Shaheen Shagufta
- Target Recruit Count
- 20
- Registration Number
- NCT01525082
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
© Copyright 2025. All Rights Reserved by MedPath